|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Gastroesophageal Reflux Disease |
|
Gastroparesis, diabetic |
|
Intubation, intestinal |
|
Nausea, postoperative |
|
Nausea, secondary to cancer chemotherapy |
|
Vomiting, postoperative |
|
Vomiting, secondary to cancer chemotherapy |
| |
|
|
SIDE EFFECTS:
|
|
Agranulocytosis |
|
cardiovascular effects, specifically hypotension |
|
hypertension |
|
tachycardia |
|
extrapyramidal effects, dystonic |
|
extrapyramidal effects, parkinsonian |
|
tardive dyskinesia |
|
Agitation |
|
panic-like sensation |
|
restless legs syndrome |
|
Diarrhea |
|
drowsiness |
|
restlessness |
|
unusual tiredness or weakness |
|
Breast tenderness and swelling |
|
changes in menstruation |
|
constipation |
|
dizziness |
|
headache |
|
insomnia |
|
mental depression |
|
prolactin stimulation |
|
nausea |
|
skin rash |
|
unusual dryness of mouth |
|
unusual irritability |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Asthma |
|
Depression, mental |
|
Hypertension |
|
Parkinson's disease |
|
>> Renal failure, severe, chronic |
|
|
ADULT DOSE:
|
|
Treatment of diabetic gastroparesis -
Oral, 10 mg (base) thirty minutes before symptoms are likely to occur or before each meal and at bedtime, up to four times a day.
Note: In the initial treatment of diabetic gastroparesis, the parenteral route of administration is recommended if severe symptoms are present. Therapy may begin at 10 mg (base) administered intramuscularly or intravenously three or four times a day, the dose adjusted as needed.
Treatment of gastroesophageal reflux -
Oral, 10 to 15 mg (base) thirty minutes before symptoms are likely to occur or before each meal and at bedtime, up to four times a day.
Note: Intermittent symptoms may be treated by taking 20 mg of metoclopramide prior to the provoking situation.
[Treatment of hiccups] -
Oral, 10 to 20 mg (base) four times a day for seven days. An initial dose of 10 mg intramuscularly may be given if necessary.
Note: In patients with renal function impairment whose creatinine clearance is less than 40 mL per minute, initial dosage should be reduced by approximately one half . |
|
MAXIMUM ADULT DOSE:
|
|
500 mcg (0.5 mg) per kg of body weight per day.
|
|
PEDIATRIC DOSE:
|
|
Gastrointestinal emptying (delayed) adjunct or
Peristaltic stimulant-
Oral, 0.1 to 0.2 mg per kg of body weight per dose, given thirty minutes before meals and at bedtime. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|